Joseph Mikhael, MD, MEd, FRCPC / Paul G. Richardson, MD - Window of Opportunity in Relapsed/Refractory Multiple Myeloma: Is There an Earlier Role for Cereblon (CRBN) E3 Ligase Modulators to Improve Patient Outcomes?

CME in Minutes: Education in Primary Care

EpisodeMay 31, 202315m

Joseph Mikhael, MD, MEd, FRCPC / Paul G. Richardson, MD - Window of Opportunity in Relapsed/Refractory Multiple Myeloma: Is There an Earlier Role for Cereblon (CRBN) E3 Ligase Modulators to Improve Patient Outcomes?

CME in Minutes: Education in Primary Care

EpisodeMay 31, 202315m

Please visit answersincme.com/EUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology and oncology discuss the role of cereblon E3 ligase modulators in patients with relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating cereblon (CRBN) E3 ligase modulators (CELMoDs) as therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM); Describe the clinical profiles of emerging CELMoDs for patients with RRMM; and Outline evidence-based strategies to optimize sequencing to CELMoDs for patients with RRMM, as they become available.

Top comments

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Primary Care by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for the busy primary care providers to cover the diagnosis, treatment, follow-up, and clinical management of various disease states. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

answersincme.com

Switch to the Fountain App

Open in Fountain